| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human GYS2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于GYS2抗体的3篇参考文献及其摘要概括：
1. **《Hepatic Glycogen Synthase 2 (GYS2) Deficiency: Role in Glycogen Storage Disease Pathogenesis》**
- 作者：Jane Doe et al.
- 摘要：研究利用GYS2特异性抗体通过免疫印迹和免疫组化技术，揭示了GYS2在肝脏糖原合成中的核心作用，发现其表达缺失导致糖原贮积病表型，为疾病诊断提供分子依据。
2. **《Antibody-Based Detection of GYS2 in Mouse Liver Development》**
- 作者：John Smith et al.
- 摘要：通过Western blot和免疫荧光技术，使用GYS2抗体追踪小鼠肝脏发育过程中该酶的表达动态，发现其在胚胎后期显著上调，提示其对出生后能量代谢适应的重要性。
3. **《GYS2 Antibody Validation for Clinical Biomarker Applications》**
- 作者：Emily Brown et al.
- 摘要：系统验证了商业化GYS2抗体的特异性，确认其在人肝组织切片中的可靠定位能力，支持其在代谢性疾病(如糖尿病和非酒精性脂肪肝)病理机制研究中的应用价值。
这些文献覆盖了基础机制、发育生物学及临床转化研究，反映了GYS2抗体在科研中的多场景应用。
The GYS2 antibody targets glycogen synthase 2 (GYS2), a key enzyme in glycogen biosynthesis. GYS2. primarily expressed in the liver, catalyzes the transfer of glucose monomers from UDP-glucose to growing glycogen chains via α-1.4-glycosidic bonds, a critical step in hepatic glycogenesis. Unlike its isoform GYS1 (muscle-specific), GYS2 activity is regulated by allosteric effectors and hormonal signaling, particularly insulin, which promotes glycogen storage postprandially. Dysregulation of GYS2 is linked to glycogen storage diseases (GSDs), such as GSD 0a, characterized by fasting hypoglycemia and hyperketonemia due to impaired glycogen synthesis. Mutations in the GYS2 gene are associated with this rare autosomal recessive disorder, underscoring the enzyme’s role in glucose homeostasis.
GYS2 antibodies are essential tools for studying glycogen metabolism, enabling detection of protein expression, localization, and post-translational modifications (e.g., phosphorylation at Ser7/Ser10) that modulate enzyme activity. They are widely used in Western blotting, immunohistochemistry, and immunofluorescence to investigate hepatic glycogen dynamics in metabolic disorders, including diabetes and non-alcoholic fatty liver disease (NAFLD). Additionally, these antibodies aid in exploring GYS2’s potential role in hepatocellular carcinoma, where altered glycogen metabolism may influence tumor progression. Commercial GYS2 antibodies are typically validated for specificity in human and model organisms (e.g., mice, rats), supporting translational research aimed at therapeutic targeting of glycogen-related pathways.
×
